Verona Pharma's Upcoming March 2025 Investor Conferences

Author: Owen Jenkins Updated: 02-18-2025 06:20 AM

Verona Pharma's Key Participation in March 2025 Investor Conferences

LONDON and RALEIGH, N.C. — Verona Pharma plc (Nasdaq: VRNA) has exciting news for investors as it prepares to showcase its advancements in the biopharmaceutical field. The company will take part in several prestigious conferences in March 2025, where senior management will present an overview of Verona Pharma and its groundbreaking initiatives.

Upcoming Conference Details

The first event on Verona Pharma's calendar is the TD Cowen 45th Annual Health Care Conference, scheduled for Monday, March 3, 2025. Management will present at 11:10 a.m. ET / 4:10 p.m. GMT in Boston, MA. This conference is a key gathering for those interested in the latest updates from health care innovators.

Shortly after, on Monday, March 10, 2025, the company's management will also attend the Leerink Partners 2025 Global Healthcare Conference. This presentation is set for 8:40 a.m. ET / 1:40 p.m. GMT in Miami, FL, offering another valuable opportunity for understanding Verona Pharma’s vision and future directions.

Webcast Availability

Investors and interested parties who want to stay updated on the conferences can access webcasts of the presentations through the Events and Presentations section found on the Company’s website. This is an excellent way to catch up on the company’s latest developments, especially for those who cannot attend in person.

Contact Information for Further Inquiries

For anyone wanting more details about Verona Pharma or the upcoming events, the company encourages reaching out through their dedicated contacts:

Verona Pharma plc
Tel: +1-844-341-9901

For investor relations, contact:
Victoria Stewart, Senior Director of Investor Relations and Communications

Email: IR@veronapharma.com

For US investor inquiries, Argot Partners can be contacted at:
Tel: +1-212-600-1902
Email: verona@argotpartners.com

International and US media inquiries should be directed to Ten Bridge Communications at:
Tel: +1-781-316-4424
Email: tbcverona@tenbridgecommunications.com

About Verona Pharma

Verona Pharma is dedicated to the development and commercialization of innovative therapies aimed at treating chronic respiratory diseases, an area of significant unmet medical needs. The company’s flagship product, Ohtuvayre™ (ensifentrine), represents a breakthrough in the maintenance treatment of COPD, combining bronchodilator and non-steroidal anti-inflammatory properties in a single inhaled therapy. Moreover, ensifentrine shows promise for the treatment of other respiratory conditions such as bronchiectasis, cystic fibrosis, and asthma.

As Verona Pharma continues to innovate and respond to critical healthcare needs, stakeholders have a compelling opportunity to understand the potential impacts of their work through these conferences.

Frequently Asked Questions

What is the purpose of the conferences Verona Pharma is attending?

The conferences allow Verona Pharma to present its latest innovations and connect with investors and stakeholders in the biopharmaceutical sector.

Where can I find the webcasts of the presentations?

The webcasts will be available in the Events and Presentations section on Verona Pharma's official website.

Who can I contact for investor inquiries about Verona Pharma?

Contact Victoria Stewart at Verona Pharma for investor inquiries via email at IR@veronapharma.com.

What is Ohtuvayre and its significance?

Ohtuvayre is Verona Pharma's leading product, combining bronchodilator and anti-inflammatory properties, making it a unique treatment for chronic respiratory diseases.

How can I get more information about Verona Pharma?

For more information, visit Verona Pharma's official website or contact their investor relations team directly.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.